# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001493152-26-022134
**Filing Date:** 2026-5
**Character Count:** 3537
**Document Hash:** f96f546487eb9b11e5a44a64326533b8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-022134.hdr.sgml**: 20260511

**ACCESSION NUMBER**: 0001493152-26-022134

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260511

**FILED AS OF DATE**: 20260511

**DATE AS OF CHANGE**: 20260511

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41677
- **FILM NUMBER:** 26960918

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May 2026

**Commission File Number: 001-41677**

**CytoMed Therapeutics Limited**

(Exact name of registrant as specified in its charter)

**1 Commonwealth Lane**

**#08-22**

**Singapore 149544**

**(Address of Principal Executive Office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

The Company today announced that its wholly owned subsidiary established in 2020, Advance Cancer Centre Pte. Ltd., has changed its name to CytoMed International Pte. Ltd., effective May 6, 2026.

The name change reflects the Company's renewed focus on expanding its international footprint, including setting up joint ventures overseas, development of international medical tourism initiatives, appointment of overseas representatives and enhancing its profile overseas. Initial geographical focus will be in Asia especially China where the Company's allogeneic gamma delta T cell technology is attracting interest from potential partners amidst China's introduction of Directive 818 which clarifies the clinical pathways.

The subsidiary's only asset at present is a 19.0% equity interest in a licenced clinic in Malaysia, with an option to increase its shareholding in the future.

The name change does not affect the subsidiary's legal entity, ownership structure, or existing contractual obligations.

Further information on our international plans will be provided once finalized. Meanwhile the Company will use its internal resources to seed this subsidiary.

For more information, please contact Evelyn Tan via email at <u>investors@cytomed.sg</u> or by telephone at +60127253505.

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CytoMed Therapeutics Limited** | **CytoMed Therapeutics Limited** |
|  | By: | */s/ CHOO Chee Kong* |
|  | Name: | CHOO Chee Kong |
| Date: May 11, 2026 | Title: | Chairman and Director |

---